time year fun continu
gener set us biotech posit result sentiment still seem
good follow strong finish experienc larg gain partial
driven aducanumab surpris cover extens continu
although noth last week investor gener get back therapeut
rotat due partli drug pricing/ hc reform drug price concern go
away anytim soon price index/ favor nation elect year
think substanti legisl unlik recal outperform
xbi nbi rel xbi nbi
highlight shift sentiment still get sens biotech investor
cautiou year elect broader macro concern strong earn cycl
good guidanc could help allay fear
continu believ macro issu unlik materi fundament
impact near-term result remain posit sector strong
fundament clear opportun out-performance remain unchang sinc
would expect better perform given mani compani benefit
season chang ahead tradit lower sale insur plan chang
year-end overal elect may impact sentiment come rhetor drug
price believ biotech fundament remain strong driven
product commerci execut
vertex look well posit anoth beat rais vertex project higher
non-gaap ep vs factset con slightli con rev
vs believ recent trikafta approv us add patient mix
ou reimburs agreement like start contribut top-line
seem well-posit us biosimilar commerci ramp
ahead consensu expect revenu cs vs factset
con non-gaap ep vs weve seen sign resili
base busi led enbrel may off-set under-perform repatha
neulasta increas due advanc pipelin could see softer guid
new cfo want give runway beat-and-rais year
regeneron dupix could drive upsid alreadi seen eylea
sale beat expect dupix also outperformkey
consensu expect sanofi collabor vs consensu
believ recent effort sanofi regeneron streamlin partnership could potenti
yield greater cost save increas effici
gilead like miss hiv revenu hiv revenu cs
vs factset think consensu expect underappreci like
cannib legaci hiv asset biktarvi absent broader strategi rejuven long-
term growth expect share weak assum hiv miss
quick hit tp chang amgen gilead vertex
galapago
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
tabl content
companydatetimedial-inpfizerjanuari etu confer id fourth quarter earningsnovartisjanuari etn/abiogenjanuari confer id etn/arochejanuari etu pm etu amgenjanuari pm etu confer id pm etu confer id neurocrinefebruari pm etu confer id nbixmerckfebruari etu confer id etn/aregeneronfebruari etu confer id n/abristol-my squibbfebruari etu passcod etu conferenec id etu confer id abbvietevafebruari etu confer id etn/aincyt februari etu etn/abayerfebruari pr releas februari et incyt bayer date/tim charl martineau pm univers toronto januari
see major surpris unlik head follow two deal
cfo transit expect continu base busi resili
commerci progress biosimilar throughout base busi
resili expect led enbrel prolia xgeva though could see continu
weak neulasta slow repatha sale enbrel ip like come
convers appeal hear could begin first week march second week april
remain confid abil defend ip met new cfo peter
griffith last week sf first opportun set guidanc discuss financi
result compani weve increas estim biosimilar franchis throughout
forecast light strong first quarter us sale ahead
consensu cs vs con also cent ahead non-gaap
ep reiter outperform rate increas tp
follow model adjust
biosimilar franchis core long-term thesi start see posit
result effort diversifi revenu base busi strong uptak
europ kanjinti herceptin biosimilar amjevita humira expect continu
us launch mvasi kanjinti outperform expect expect
continu uptak drive revenu ahead consensu contribut avsola
compani remicad biosimilar formerli abp approv decemb continu
believ biosimilar franchis posit favor drug price debat return
spotlight ahead us presidenti elect
focu point call expect compani provid guidanc includ
revenu non- ep non- tax rate capit expenditur
new cfo could guid conserv believ could set beat
rais year commerci front expect detail updat regard
on-going us biosimilar launch includ avsola abp listen
increment detail confirm get addit data tezepelumab
asthma data expect later year phase data ad yet confirm
beigen collabor well commentari otezla integr
risk tp rate clinic development commerci regulatori
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
inc biotechnolog compani engag discoveri
develop manufactur market human therapeut
blue sky scenario assum tvgr better current
assumpt base-busi greater current
forecast assum greater expect growth biosimilar
franchis slower expect declin base busi
also assum posit data readout pipelin asset
base busi sale poorer growth profil biosimilar
busi key pipelin asset assum slower expect
growth biosimilar franchis regulatori headwind drug
approv ip litig also assum neg data readout
 close
model chang valuat weve increas biosimilar sale beyond
given better expect perform driven us launch forecast
biosimilar sale slightli off-set fewer expect share
repurchas given current share valuat lower non-gaap ep
valuat price target deriv dcf analysi use wacc
termin growth forecast cash flow account known expect
product launch patent expir competit threat current commerci
portfolio pipelin
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv investig product
commerci sale
result unlik reveal gilead chapter despit believ still
best-in-class hiv franchis hiv revenu cs vs
think consensu expect underappreci like cannib legaci hiv
asset biktarvi consequenti cent non-gaap ep consensu
would expect share trade hiv miss although could see minim
upsid specif strategi rejuven long-term growth announc accret
large-scal unlik view think con expect hiv
franchis remain high longer term vs cs project slower
overal remain concern earn revenu growth long-term cs sale vs
consensu coupl recent nash failur potenti commerci challeng
filgotinib rel thin pipelin believ mani investor seem becom impati
overal strategi yet materi ceo oday compani
capac transact seen difficult extract addit valu
pharmasset vs kite absent clear strategi re-acceler growth reiter
under-perform rate lower tp increas execut risk
focu point call expect guidanc product sale gross margin expens
sg expens effect tax rate compani provid ep guidanc
call follow commentari last week look updat overal strategi year
potenti hint anticip ceo oday could outlin manag
chang affect broader strategi gilead may also discuss expect
filgotinib commerci consider final would expect hear gilead
posit nash franchis given recent failur atla trial
model changes/valu weve decreas revenu reflect
appropri trajectori consist prior quarter result non-gaap
ep decreas tp chang
view decreas tp reflect increas execut risk base strategi weve seen
emerg last year senior manag
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
inc biopharmaceut compani engag
research develop commerci medicin
area infecti diseas oncolog immunolog area
sky scenario model probabl success
yescarta expans well filgotinib also assum success
mid-stag nash asset exclud selonsertib maintain base
case third line yescarta hiv hcv sale
grey sky scenario model car-t platform
success beyond dlbcl filgotinib program delay fail
meet base-cas expect nash program fail
maintain base case third line yescarta hiv hcv sale
 close
risk tp rate clinic development commerci regulatori
model chang weve decreas revenu royalti contract
reflect appropri trajectori consist prior quarter increas
product sale result move legaci product product sale sale
get charg opex result
valuat target price deriv dcf analysi use wacc
termin growth forecast cash flow account known expect
product launch patent expir competit threat current commerci
portfolio pipelin
view decreas tp reflect increas execut risk base strategi weve
seen emerg last year senior manag includ galapago
partnership add element risk overal busi filgotinib nearli year behind
rinvoq significantli differenti econom eu depend
galapago first-tim commerci biktarvi cannib like caus volatil
sale vs consensu estim hiv franchis meet consensu partial depend
truvada descovi prep convers truvada gener may hit later year consensu
truvada number potenti high like mis-model descovi convers
potenti impact gener given current market condit gilead less less like
find accret bd given core compet infecti diseas rich biotech valuat
meanwhil gilead demonstr track record overpay asset
gilead axicabtagen franchis ex product revenu includ glpg incom cs loss incom cs dilut cs charl martineau pm univers toronto januari
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv gilead investig product
commerci sale
anoth beat rais stori vertex believ conserv expect
coupl underappreci cf opportun drive share out-performance
believ recent approv trikafta us last year layer addit revenu
cs vs visibl alpha patient cover ou sale sever
reimburs agreement reach recent variou cf drug uk franc spain
australia add increment revenu believ well repres
current expect progress toward agreement ou repres addit
upsid particularli full portfolio franc end ahead cf revenu
cs vs addit non-gaap ep cs vs furthermor
larg expect approv trikafta eu could expand cf opportun
cf remain core vertex op thesiswith forecast ww revenu
long-term look updat key pipelin asset fsg scd/beta-th
thesi predic mainli cf revenu believ progress made
pipelin could provid addit upsid base case get sens earlier-
stage primarili pre-clin platform remain core vertex bd goal like
see smaller deal throughout year overal continu believ vertex one
best growth profil among peer believ vertex track record develop novel
pipelin asset give us greater convict one sever potenti succeed
result rais tp pipelin start play
relev role vertex
focu point call look specif regard overal strategi
receiv less specif particularli given last year announc manag chang
believ incom ceo/curr reshma kewalramani like outlin vision
strateg prioriti next year may get increment detail trikafta
launch progress furthermor expect specif time could see data
pipelin asset fsg scd/beta-th
model changes/risk make chang estim howev
increas termin valu assumpt account greater strateg
emphasi develop pipelin risk clinic development commerci regulatori
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
vertex engag develop commerci therapeut
rare diseas includ main franchis cystic fibrosi
scenario assum dcf valu share
cut sg respect assum
posit proof-of-concept data next gener cf asset
also assum posit data updat pipelin asset vx-
gene-edit system
grey sky scenario model less credit trikafta due
lower expect commerci perform regulatori delay
 close
model chang increas termin valu assumpt
account greater strateg emphasi develop pipelin given new ceo strategi
diversifi beyond cf revenu greater convict vertex success
develop novel non-cf asset futur
valuat target price deriv dcf analysi use wacc
termin growth forecast cash flow account known expect
product launch patent expir competit threat current commerci
portfolio pipelin
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv vertex investig product
commerci sale
vertex residu cf opportun ex cf opportun ex revenu loss incom cs dilut cs charl martineau pm univers toronto januari
result matter aducanumab result tecfidera ipr matter
slightli ahead earn given recent share buyback resili base
busi view aducanumab remain key driver share given
import asset compani adj peak sale po
get aducanumab updat also expect result tecfidera ipr februari
could impact ms franchis trajectori near-term given event
expect share remain flat slightli earningscommentari spinraza
even posit unlik much stock point get sens
investor focus around time regulatori file rel quiet
far detail move asset forward given discrep data present
ctad decemb remain cautiou absent detail bla file commerci
considerationssupport neutral rate still believ suffici
momentum ultim file gain fda approv look greater clariti
increas confid
forecast consensu revenu vs cost manag
share repurchas could drive modest ep beat believ spinraza may
under-perform cs vs con due on-going impact zolgensma risdiplam
also come may also expect biosimilar eros impact rituxan sale cs
vs con howev oper expens manag share buyback may
contribut ep expect cs vs con howev longer-
term still signific concern mani headwind still exist tecfidera ipr potenti
competit sma risdiplam zolgensma less lower impact pipelin exclud
aducanumab broader issu may prove less relev compani
success commerci aducanumab non-gaap ep ahead
consensu expens manag
focu point call expect follow guidanc metric revenu
expens revenu sg expens revenu tax rate fd ep
could get addit commentari around aducanumab file applic even
accepted/ reject fda expect much could also get thought
ms busi sma franchis pipelin asset
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc biopharmaceut compani engag
discov develop deliv therapi neurolog
experi greater expect degre eros
competit eros occur partial off-set sale
vumer spinraza remain standard care sma risdiplam
zolgensma either fail clinic take meaning share
aducanumab approv use major address patient
grey scenario assum ms franchis declin greater
expect rate new therapi take greater expect share
near-term zolgensma captur major new incid
sma market long-term spinraza lose share risdiplam
preval sma market aducanumab approv
 close
model chang increas estim rituxan slightli given rel
strength first three quarter base forecast non-
gaap ep
inc ms product biosimilar revenu incom dilut charl martineau pm univers toronto januari
upbeat dupix like continu drive mab jv profit
long-term increasingli construct regeneron emerg oncolog
portfolio regeneron alreadi report us eylea sale
expect compani beat revenu driven partli strong uptak dupix dupix
outperform expect far despit signific competit asthma atop
dermat space encourag recent commentari partner sanofi dupix
could reach eur long-term furthermor believ recent effort compani
streamlin partnership could yield greater cost save increas effici
long-term estim eylea outperform consensu expect like
overestim competit beovu potenti impact healthcar reform
forecast compound-annual-growth-rate growth vs con compound-annual-growth-rate declin model
take account biosimilar long-term note recent launch pre-fil syring
add anoth moat around franchis also believ reimburs risk eylea
declin rel expect medicar part overhaul appear unlik
ahead elect though renew interest ipi/u favor nation price may
caus sentiment-driven volatil ahead consensu sanofi collabor
revenu estim vs driven improv jv
profit mab sale mileston payment continu believ limit valu
assign emerg oncolog portfolio current valuat posit updat libtayo
bispecif platform could driver upsid overal think set
regeneron favor underappreci upsidedriven eylea dupix
emerg oncolog pipelin reiter outperform rate top pick
tp
focu point call current expect financi guidanc call
pend complet collabor restructur also look discuss around
recent commentari sanofi regeneron streamlin partnership may get
updat emerg novel oncolog portfolio believ becom increasingli
import driver compani
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc engag discoveri invent
develop manufactur commerci medicin
treatment seriou diseas
blue sky scenario assum better expect sale
dupix praluent kevzara libtayo eylea
grey sky scenario assum lower forecast
competit across core busi eylea dupix praluent
libtayo kevzara
 close
model chang made minor chang model includ us eylea sale
report last week vs previous estim
million priorcurrentchangepriorcurrentchangepriorcurrentchangeeylea collabor mab revenu reimburs reimburs loss incom dilut charl martineau pm univers toronto januari
in-lin jakafi believ opportun fairli valu current share price
estim us jakafi sale in-lin factset compani provid
consensu cs vs compani provid continu believ jakafi
remain market leader myelofibrosi polycythemia vera near-term potenti
upsid less like believ current share price fairli valu opportun
peak us sale view investor seem less impress recent morphosi deal
follow announc last week addit color might help market
warm stori expect launch tafasitamab us eu mid-
rest market portfolio believ iclusig cs vs compani
provid olumi royalti cs vs compani provid rel in-line
expect
look believ becom urgent deliv posit result
pipelin asset given recent failur itacitinib view pipelin need
addit time advanc meaning diversifi revenu jakafi think
higher valu asset like pemigatinib bladder cancer larger indic vs cholangiocarcinoma
tumor agnost set would like reduc relianc jakafi limit
visibl indic topic ruxolitinib could potenti strong asset diversifi
revenu await upcom data readout atop dermat
year look detail around higher valu asset later year
reiter neutral rate
focu point call look updat guidanc compani usual
provid benchmark us jakafi revenu iclusig eu expens like give
greater detail possibl expect tafasitamab follow last week deal
morphosi also interest hear jakafi combin trial pim
bet recent mention limit improv efficaci ultim increas
drug life cycl
model chang estim tp rate remain unchang
risk tp rate clinic development commerci regulatori
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
incyt corp biopharmaceut compani engag
discoveri develop commerci proprietari therapeut
oncolog hematolog dermatolog
blue sky upsid case valuat base fda
approv pemigatinib cholangiocarcinoma within next
month also assum better expect jakafi revenu
grey sky downsid valuat assum fda
approv pemigatinib grey sky also assum neg data readout
pemigatinib urotheli cancer also assum jakafi revenu
lower expect
 close
model chang made chang tp rate non-gaap dilut ep
remain unchang updat model reflect recent ink partnership
morphosi transact close
incyt corpor million priorcurrentchangepriorcurrentchangepriorcurrentchangejakafi ruxolitinib sale ruxolitinib royalti revenu loss incom cs dilut cs charl martineau pm univers toronto januari
expect quieter quarter focu remain filgotinib launch acceler
toledo program weve made minor model adjust adjust financi
expens assumpt reflect view spend seen unlik recur
rate galapago head see reduc overal risk compani go
forward though outlook remain neutral rel basi peer believ may
challeng compani deliv market return given larg cash balanc
competit filgotinib pipelin either challeng indic develop ipf
low visibl asset toledo compani substanti cash reserv
eur provid down-sid valuat support cash balanc sheet contribut
signific portion valuat still believ collabor gilead mitig
execut risk galapago monet much pipelin like benefit
gilead commerci develop expertis weve increas tp
reflect galapago de-risk profil head compani
transit develop commerci believ current trade
price adequ valu known opportun
follow galapago day novemb believ acceler pipelin
like take time encourag toledo franchis plan multipl studi
initi slate find challeng valu potenti opportun given lack
visibl program latest updat day lack granular would
help us better valu toledo present suggest data updat like
toward given plan initi trial absent data definit
timelin toledo remain conserv view program need see
evid execut adjust long-term growth assumpt
model chang weve lower recur financi expens assumpt throughout
forecast weve adjust valuat assumpt discount rate reflect risk
mitig gilead transact galapago transit commercial-stag compani
valuation/risk tp base sum part dcf analysi ep
chang risk commerci market price regulatori
valuat metric
number share
amsterdam exchang close
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
galapago clinic stage biotech compani focus develop
novel treatment rheumatoid arthriti inflammatori bowel diseas
idiopath pulmonari fibrosi atop dermat
blue sky valuat base po filgotinib
rheumatoid arthriti ulcer coliti crohn diseas well
better-than-expect data pipelin drug
grey sky valuat base clinic failur
development pipelin includ eur valu cash-on-
hand adjust gilead transact
amsterdam exchang close
model chang reduc dcf discount rate due
gilead partnership believ reduc commerci develop risk
allow galapago monet asset earlier long run given galapago signific cash
posit expect continu invest like gener revenu via bd
overal effect chang result increas target price
forecast ep
valuat price target deriv dcf analysi use wacc
termin growth forecast cash flow account known expect
product launch patent expir competit threat current commerci
portfolio pipelin
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv galapago investig
product commerci sale
galapago nv eu sale revenu incom loss expens incom cs dilut cs charl martineau pm univers toronto januari
see limit upsid earn follow ingrezza sale pre-announc last
week despit decent ingrezza beat vs consensu
announc ahead continu believ current trade level fairli valu
opportun get sens investor expect ahead sell-sid consensu
believ beat larg expect neurocrin also benefit
inventori due quarter end-purchas maintain sell-sid consensu number
ingrezza peak could see tighter spread go forward sell-sid
investor expect look orilissa royalti slightli ahead
expect cs vs continu expect broader headwind em indic
believ compani still lack near-term asset like diversifi revenu
away ingrezza meaning think opicapon sale orilissa royalti
suffici significantli diversifi revenu base meanwhil label expans
huntington diseas could add increment revenu franchis data remain
unlik significantli alter trajectori pipelin start becom
relev stori could potenti see sentiment driven upsid surround data
releas howev remain conserv data avail particularli
voyag collabor reiter tp neutral rate
focu point call expect sale guidanc ingrezza could get
color contract season dynam go forward might hear
potenti commerci launch opicapon pdufa along orilissa uf
expect approv mani key mileston alreadi discuss
last week may hear detail expect voyag collabor implement
vy-aadc amend protocol restore-i registr studi mid-year base fda
feedback initi restore-ii registr trial
model chang project non-gaap ep driven
updat ingrezza revenu report last week lower expect opicapon
chang market assumpt make chang target price rate
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc commercial-stag biopharmaceut
compani discov develop intend commerci drug
treatment neurolog endocrin relat diseas
blue sky valuat base fda approv elagolix
uterin fibroid opicapon parkinson diseas also assum
posit pivot congenit adren hyperplasia
posit data gene therapi asset vy-aadc
voyag transact furthermor assum better expect
growth ingrezza orilissa endometriosi
grey sky valuat assum fda approv elagolix
uterin fibroid opicapon parkinson diseas assum
neg top-line pivot congenit adren hyperplasia
grey sky also assum lower expect revenu ingrezza
 close
neurocrin revenu incom loss expens incom cs dilut cs charl martineau pm univers toronto januari
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
